Standard of care for muscle-invasive bladder cancer is cisplatin-based combination neoadjuvant chemotherapy (NAC) then radical cystectomy and lymph node dissection. This article reviews how NAC reduces the risk for recurrence.
The immune checkpoint inhibitor atezolizumab showed promising, lasting efficacy in patients with locally advanced or metastatic urothelial cancer, according to results of a phase II clinical trial conducted by an international team including Cleveland Clinic Cancer Center oncologist Petros Grivas, MD, PhD. The findings represent the first significant improvement in the systemic treatment of metastatic urothelial cancer in 30 years.
Researchers find that, in advanced urothelial cancer, improved response to atezolizumab may be predicted by PD-L1 expression, cancer genome subtype and mutational load.
Patients with metastatic or locally advanced urothelial cancer treated with chemotherapy, or those who are not candidates for cisplatin-based chemotherapy, may have hope in newer immunotherapeutic agent pembrolizumab.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
An innovative nationwide clinical trial will test the efficacy of matching a tumor’s molecular profile to targeted agents to treat patients with advanced solid tumors or lymphomas.
Two new clinical trials are meant to improve outcomes and quality of life for patients with advanced bladder cancers. One is for localized, muscle-invasive tumors; the other is for platinum-refractory advanced/metastatic urothelial cancer.